Annual CFO
-$18.87 M
-$4.17 M-28.41%
December 31, 2023
Summary
- As of February 12, 2025, GANX annual cash flow from operations is -$18.87 million, with the most recent change of -$4.17 million (-28.41%) on December 31, 2023.
- During the last 3 years, GANX annual CFO has fallen by -$15.63 million (-482.24%).
- GANX annual CFO is now -2434.04% below its all-time high of -$744.50 thousand, reached on December 31, 2018.
Performance
GANX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$6.08 M
-$319.80 K-5.56%
September 30, 2024
Summary
- As of February 12, 2025, GANX quarterly cash flow from operations is -$6.08 million, with the most recent change of -$319.80 thousand (-5.56%) on September 30, 2024.
- Over the past year, GANX quarterly CFO has dropped by -$415.80 thousand (-7.35%).
- GANX quarterly CFO is now -1332.39% below its all-time high of -$424.20 thousand, reached on June 30, 2020.
Performance
GANX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$21.08 M
-$2.11 M-11.12%
September 30, 2024
Summary
- As of February 12, 2025, GANX TTM cash flow from operations is -$21.08 million, with the most recent change of -$2.11 million (-11.12%) on September 30, 2024.
- Over the past year, GANX TTM CFO has dropped by -$2.21 million (-11.73%).
- GANX TTM CFO is now -2700.16% below its all-time high of -$752.80 thousand, reached on March 31, 2020.
Performance
GANX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
GANX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -28.4% | -7.3% | -11.7% |
| 3 y3 years | -482.2% | -46.5% | -70.5% |
| 5 y5 years | -2434.0% | -46.5% | -70.5% |
GANX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -52.6% | at low | -148.3% | at low | -75.6% | at low |
| 5 y | 5-year | -909.7% | at low | -1332.4% | at low | -2700.2% | at low |
| alltime | all time | -2434.0% | at low | -1332.4% | at low | -2700.2% | at low |
Gain Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$6.08 M(+5.6%) | -$21.08 M(+11.1%) |
| Jun 2024 | - | -$5.76 M(+60.5%) | -$18.97 M(+4.0%) |
| Mar 2024 | - | -$3.59 M(-36.6%) | -$18.24 M(-3.3%) |
| Dec 2023 | -$18.87 M(+28.4%) | -$5.66 M(+42.7%) | -$18.87 M(+10.3%) |
| Sep 2023 | - | -$3.97 M(-21.0%) | -$17.11 M(+4.1%) |
| Jun 2023 | - | -$5.02 M(+19.1%) | -$16.43 M(-0.2%) |
| Mar 2023 | - | -$4.22 M(+8.0%) | -$16.46 M(+12.0%) |
| Dec 2022 | -$14.69 M(+18.8%) | -$3.90 M(+18.7%) | -$14.69 M(-1.6%) |
| Sep 2022 | - | -$3.29 M(-34.9%) | -$14.93 M(+7.9%) |
| Jun 2022 | - | -$5.05 M(+106.4%) | -$13.84 M(+15.3%) |
| Mar 2022 | - | -$2.45 M | -$12.00 M |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | -$12.37 M(+281.6%) | - | - |
| Dec 2021 | - | -$4.15 M(+89.1%) | -$12.37 M(+29.8%) |
| Sep 2021 | - | -$2.19 M(-31.9%) | -$9.53 M(+17.8%) |
| Jun 2021 | - | -$3.22 M(+14.5%) | -$8.09 M(+52.7%) |
| Mar 2021 | - | -$2.81 M(+114.8%) | -$5.30 M(+63.5%) |
| Dec 2020 | -$3.24 M(+73.4%) | - | - |
| Dec 2020 | - | -$1.31 M(+73.3%) | -$3.24 M(+67.7%) |
| Sep 2020 | - | -$755.00 K(+78.0%) | -$1.93 M(+64.1%) |
| Jun 2020 | - | -$424.20 K(-43.7%) | -$1.18 M(+56.3%) |
| Mar 2020 | - | -$752.80 K | -$752.80 K |
| Dec 2019 | -$1.87 M(+151.0%) | - | - |
| Dec 2018 | -$744.50 K | - | - |
FAQ
- What is Gain Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Gain Therapeutics?
- What is Gain Therapeutics annual CFO year-on-year change?
- What is Gain Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Gain Therapeutics?
- What is Gain Therapeutics quarterly CFO year-on-year change?
- What is Gain Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Gain Therapeutics?
- What is Gain Therapeutics TTM CFO year-on-year change?
What is Gain Therapeutics annual cash flow from operations?
The current annual CFO of GANX is -$18.87 M
What is the all time high annual CFO for Gain Therapeutics?
Gain Therapeutics all-time high annual cash flow from operations is -$744.50 K
What is Gain Therapeutics annual CFO year-on-year change?
Over the past year, GANX annual cash flow from operations has changed by -$4.17 M (-28.41%)
What is Gain Therapeutics quarterly cash flow from operations?
The current quarterly CFO of GANX is -$6.08 M
What is the all time high quarterly CFO for Gain Therapeutics?
Gain Therapeutics all-time high quarterly cash flow from operations is -$424.20 K
What is Gain Therapeutics quarterly CFO year-on-year change?
Over the past year, GANX quarterly cash flow from operations has changed by -$415.80 K (-7.35%)
What is Gain Therapeutics TTM cash flow from operations?
The current TTM CFO of GANX is -$21.08 M
What is the all time high TTM CFO for Gain Therapeutics?
Gain Therapeutics all-time high TTM cash flow from operations is -$752.80 K
What is Gain Therapeutics TTM CFO year-on-year change?
Over the past year, GANX TTM cash flow from operations has changed by -$2.21 M (-11.73%)